{
  "meta": {
    "data_length": 1,
    "message": "Indication id ind:ema.lynparza:6 retrieved successfully",
    "request_url": "http://api.moalmanac.org/indications?indication_id=ind%3Aema.lynparza%3A6",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.003622,
    "timestamp_received": "2026-04-24T15:54:50.159427+00:00Z",
    "timestamp_returned": "2026-04-24T15:54:50.163049+00:00Z",
    "trace_id": "f3d03b49-e66b-4158-aec5-734d65299b2f"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://dev.moalmanac.org",
    "last_updated": "2026-04-09"
  },
  "data": [
    {
      "id": "ind:ema.lynparza:6",
      "indication": "Lynparza in combination with durvalumab is indicated for the maintenance treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair proficient (pMMR) whose disease has not progressed on first-line treatment with durvalumab in combination with carboplatin and paclitaxel.",
      "initial_approval_date": "2024-08-20",
      "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/lynparza-h-c-ws2463-epar-assessment-report-variation_en.pdf",
      "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with durvalumab for the maintenance treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair proficient (pMMR) whose disease has not progressed on first-line treatment with durvalumab in combination with carboplatin and paclitaxel.",
      "raw_biomarkers": null,
      "raw_cancer_type": "Endometrial cancer",
      "raw_therapeutics": "Lynparza (olaparib) in combination with durvalumab for maintence treatment, after not progressing on first-line treatment with durvalumab in combination with carboplatin and paclitaxel",
      "icd10": null,
      "regimen_code": null,
      "reimbursement_category": null,
      "reimbursement_date": null,
      "reimbursement_details": null,
      "date_regular_approval": null,
      "date_accelerated_approval": null,
      "document": {
        "id": "doc:ema.lynparza",
        "type": "Document",
        "documentType": "Regulatory approval",
        "name": "Lynparza (olaparib) [product information]. EMA.",
        "title": null,
        "aliases": [],
        "description": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.",
        "urls": [
          "https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza",
          "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf"
        ],
        "doi": null,
        "pmid": null,
        "extensions": [
          {
            "name": "agent",
            "value": {
              "id": "ema",
              "type": "Agent",
              "agentType": "organization",
              "name": "European Medicines Agency",
              "description": "Regulatory agency that approves medicines for use in the European Union.",
              "extensions": [
                {
                  "name": "last_updated",
                  "value": "2025-10-01",
                  "description": ""
                },
                {
                  "name": "url",
                  "value": "https://www.ema.europa.eu/en/medicines",
                  "description": ""
                }
              ]
            },
            "description": "The organization that published this document."
          },
          {
            "name": "company",
            "value": "AstraZeneca AB.",
            "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_brand",
            "value": "Lynparza",
            "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_generic",
            "value": "olaparib",
            "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "first_publication_date",
            "value": "2015-01-09",
            "description": "The publication date for the initial version of this document."
          },
          {
            "name": "identification_number",
            "value": null,
            "description": "Identification number used by the publishing organization."
          },
          {
            "name": "publication_date",
            "value": "2024-08-20",
            "description": "The publication date for the document."
          },
          {
            "name": "status",
            "value": "Active",
            "description": "Whether this document is Active or Deprecated within moalmanac-db."
          }
        ]
      }
    }
  ]
}